10 Best Genomics Stocks To Buy Right Now
Genomics is the study of genes and how they function.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 266,236 | $279,877,933 | +5% | 0.24% |
| 2. | AQR Capital Management Cliff Asness | 225,534 | $235,232,332 | +20% | 0.32% |
| 3. | Renaissance Technologies Jim Simons | 211,423 | $222,256,315 | +15% | 0.33% |
| 4. | Millennium Management Israel Englander | 201,174 | $211,482,156 | -25% | 0.1% |
| 5. | 200,900 | $211,194,116 | +41% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | 23,880,537 | 2017-08-25 | Filing | ||
| $485.99 | 2,681 | 23,877,980 | 2017-08-25 | Filing | ||
| $485.28 | 5,723 | 23,875,299 | 2017-08-25 | Filing | ||
| $484.21 | 2,000 | 23,869,576 | 2017-08-25 | Filing | ||
| $482.87 | 4,485 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $844.61 | 1,000 | Officer | 12,931 | 2024-11-01 | Filing | |
| $1,059.28 | 2 | Director | 17,582 | 2024-10-01 | Filing | |
| $1,057.38 | 2 | Director | 17,584 | 2024-10-01 | Filing | |
| $1,056.68 | 3 | Director | 17,586 | 2024-10-01 | Filing | |
| $1,054.90 | 3 | Director | 17,589 | 2024-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,317,415 | $9,061,682,469 | 0.69% | |
| 2. | 8,838,285 | $7,762,577,333 | 0.16% | |
| 3. | 8,629,707 | $7,579,385,538 | 0.19% | |
| 4. | 7,226,769 | $6,347,199,734 | 0.67% | |
| 5. | 5,130,485 | $4,506,070,906 | 0.8% |
News See All
Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3
Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2024 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2024 Earnings Call Transcript October 31, 2024Regeneron Pharmaceuticals, Inc. beats earnings expectations.
What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 High Growth NASDAQ Stocks That Are Profitable in 2024
Malcolm Ethridge, Capital Area Planning Group managing partner, joined CNBC to talk about where the market could go and his sentiment regarding the AI and overall tech sector.
10 Buzzing AI Health Stocks
The economic impact of AI is projected to be substantial, particularly in regions like China and North America, which are expected to see GDP boosts of 26% and 14.5%, respectively, by 2030, amounting ...
Morgan Stanley's Best Overweight & Quality Stocks: Top 25 Stocks
The close of September has cemented the paradigm shift on Wall Street.
Cramer's Morning Thoughts: 20 Stocks to Watch
In a recent episode of Mad Money, Jim Cramer explains that if you're investing with real money, not just playing a simulation like a stock market game, it’s essential to open a real investment account...
Jim Cramer’s Must-Watch List: 10 Stocks to Look After
In a recent episode of Mad Money, Jim Cramer explained that with the economy slowing down, the Federal Reserve is poised to ease its policies.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2024 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2024 Earnings Call Transcript August 1, 2024Regeneron Pharmaceuticals, Inc. beats earnings expectations.
Billionaire Hedge Funds
